Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
Authors:
- William JuguetWJWilliam Juguet
- Damien FardDFDamien Fard
- Laureline FaivreLFLaureline Faivre
- Athanasios KoutsoukisAKAthanasios Koutsoukis
- Camille DeguillardCDCamille Deguillard
- Nicolas MongardonNicolas Mongardon
- Armand Mekontso-DessapAMArmand Mekontso-Dessap
- Raphaelle HuguetRHRaphaelle Huguet
- Pascal LimPLPascal Lim
Open Access
- 9 November 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3605
Abstract
Randomized studies showed that Dobutamine and Levosimendan have similar impact on outcome but their combination has never been assessed in acute decompensated heart failure (ADHF) with low cardiac output. This is a retrospective, single-center study that included 89 patients (61 ± 15 years) admitted for ADHF requiring inotropic support. The first group consisted of patients treated with dobutamine alone (n = 42). In the second group, levosimendan was administered on top of dobutamine, when the superior vena cava oxygen saturation (ScVO2) remained 60%) was reached in 36% and 32% of patients in the dobutamine and dobutamine-levosimendan group, respectively. After adding levosimendan, 72% of the dobutamine-levosimendan-group reached the ScVO2 target value at dobutamine weaning. At six months, 42 (47%) patients experienced MACE (n = 29 for death). MACE was less frequent in the dobutamine-levosimendan (32%) than in the dobutamine-group (64%, p = 0.003). Independent variables associated with outcome were admission systolic blood pressure and dobutamine-levosimendan strategy (OR = 0.44 (0.23–0.84), p = 0.01). In conclusion, levosimendan added to dobutamine may improve the outcome of ADHF refractory to dobutamine alone.Keywords
This publication has 23 references indexed in Scilit:
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trialsIntensive Care Medicine, 2011
- Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart FailureJAMA, 2007
- Reassessment of Dobutamine, Dopamine, and Milrinone in the Management of Acute Heart Failure SyndromesThe American Journal of Cardiology, 2005
- Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine aloneThe American Journal of Cardiology, 2004
- The Effectiveness and Relative Effectiveness of Intravenous Inotropic Drugs Acting Through the Adrenergic Pathway in Patients with Heart Failure—A Meta-Regression AnalysisEuropean Journal of Heart Failure, 2002
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic ShockNew England Journal of Medicine, 2001
- Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failureJACC, 2000